Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

Executive Summary

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Advertisement

Related Content

Pfizer On Reorganizing, M&A And Investing In Internal R&D
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Trump Tries To Shame A Defiant Pfizer On Drug Pricing
Pfizer's Xeljanz: The Slow Road To Blockbuster Status

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel